Skip to primary navigation Skip to main content
0 item $0.00

Using biotechnological tools, we are developing drugs that will be enriched at areas of thrombosis or inflammation without reaching a significant systemic circulating concentration. This allows for example to develop anti-thrombotic, anti-platelet or clot-busting drugs that are highly effective but do not cause bleeding complications. The transport and enrichment of these drugs is achieved by using nanoparticles, liposomes, microbubbles and other high end targeting particles. In addition to targeting drugs, we have also developed a recombinant antibody delivery system that allows to specifically deliver stem cells as a regenerative cell therapeutic approach, (e.g. for the therapy of myocardial infarction).

Student research opportunities

Beginning your research career with one of Australia's largest medical research institutes provides unique opportunities for Masters, Honours and PhD students.

Find out more